Cell Therapeutics Announces Removal of Partial Clinical Hold on Tosedostat Print E-mail
By Staff and Wire Reports   
Thursday, 02 January 2014 19:19
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 2, 2014.

Cell Therapeutics (NASDAQ: CTIC)
announced it has received notification from the U.S. FDA that the partial clinical hold on tosedostat (IND 075503) has been removed and all studies underway may continue.

Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor cell survival, and is under development for the treatment of blood-related cancers. Tosedostat is currently being studied in the United States and European Union in investigator-sponsored and cooperative group-sponsored Phase 2 trials in elderly patients with newly diagnosed and relapsed acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).

"We are pleased that the FDA has responded favorably to the tosedostat clinical trial data provided and removed the partial clinical hold to allow further development of tosedostat in ongoing and future studies," said John Pagel, MD, PhD, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Associate Professor, Medical Oncology Division, University of Washington School of Medicine; and Principal Investigator in the tosedostat first-line AML/MDS trial.



Also Thursday:



Advanced Cannabis Solutions (OTCQB: CANN)
announced today that it has successfully met the minimum capital raise requirements for its current $5 million convertible debt placement.

athenahealth, Inc. (Nasdaq:ATHN)
, a leading provider of cloud-based services for electronic health record (EHR), practice management, and care coordination, today announced data that shows the steepest rise in flu rates across the U.S. this season, as well as detail on the top ten most flu-impacted states.

AV Therapeutics, Inc. (OTCQB:AVTH)
, a developer of cancer therapeutics and vaccines, announced that its common stock began trading on the OTC Market Group's OTCQB Marketplace ("OTCQB") under the symbol "AVTH" on December 27, 2013.

Cannabis Sativa, Inc. (OTCBB:CBDS)
announced today that on January 1, 2014, it has signed an agreement to purchase a patent pending for a new, super potent medicinal cannabis strain.

Champions Oncology (OTC:CSBR)
, a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today that its Baltimore, MD-based laboratory has received accreditation from The Joint Commission.

Enzymotec Ltd. (Nasdaq:ENZY)
, a developer, manufacturer and marketer of innovative bio-functional lipid ingredients, announced today that it has appointed Steve Dubin as Chairman of its board of directors, effective January 1, 2014.

LeMaitre Vascular, Inc. (Nasdaq:LMAT)
, a provider of peripheral vascular devices and implants, announced today that it has begun selling Direct-to-Hospital in Australia and Norway in January 2014.

Mylan Inc. (Nasdaq: MYL)
, one of the world's leading generic and specialty pharmaceutical companies, today announced that CEO Heather Bresch will present at the Goldman Sachs Healthcare CEOs Unscripted: A View From the Top Conference on Tuesday Jan. 7, 2014, in Boston.

Neogen Corporation (NASDAQ: NEOG)
announced today that it has acquired the stock of Chem-Tech Ltd., a manufacturer of insecticides for the animal and food industries.

NeoStem, Inc. (Nasdaq:NBS)
, a leader in the emerging cellular therapy industry, announced today that the Company and its subsidiary, Progenitor Cell Therapy, LLC ("PCT"), will present at multiple upcoming conferences in January.

PAREXEL International Corporation (Nasdaq:PRXL)
will release financial results for the Second Quarter of Fiscal Year 2014 on Wednesday, January 29, 2014 after the close of the stock market.

Stellar Biotechnologies, Inc. (OTCQB: SBOTF) (TSX VENTURE: KLH)
, announced today the filing of its annual report for the fiscal year ended August 31, 2013 and financial results and operational highlights for 2013.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter